Back to Search
Start Over
Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: analysis on cytokines and lipid profile
- Source :
- Atherosclerosis Plus, Vol 43, Iss, Pp 7-9 (2021)
- Publication Year :
- 2021
- Publisher :
- Elsevier B.V., 2021.
-
Abstract
- Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.
- Subjects :
- Drug
medicine.medical_specialty
media_common.quotation_subject
Familial hypercholesterolemia
PCSK9
chemistry.chemical_compound
Internal medicine
Lomitapide, Lipoprotein (a), PCSK9, Familial Hypercholesterolemia
Lipoprotein (a)
Internal Medicine
medicine
Diseases of the circulatory (Cardiovascular) system
Familial Hypercholesterolemia
skin and connective tissue diseases
media_common
Ldl cholesterol
medicine.diagnostic_test
business.industry
nutritional and metabolic diseases
Plasma levels
medicine.disease
Lomitapide
lp(a)
Endocrinology
chemistry
RC666-701
pcsk9
lipids (amino acids, peptides, and proteins)
sense organs
Cardiology and Cardiovascular Medicine
Lipid profile
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Atherosclerosis Plus, Vol 43, Iss, Pp 7-9 (2021)
- Accession number :
- edsair.doi.dedup.....4cd5f3978214c9bbeb98864d8713492e